Our study found that HER2 amplification altered the transcriptomic profiles in DCIS, and particularly, interferon signaling pathway was activated by HER2 amplification in DCIS, which may provide a prolonged interferon signaling activation in HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.